1 / 35

Principles of WHO Guidelines on nonclinical evaluation of vaccines.

Principles of WHO Guidelines on nonclinical evaluation of vaccines. Jan Willem van der Laan Pharmacological-Toxicological Assessment Section Centre for Biological Medicines and Medical Technology National Institute for Public Health and the Environment, Bilthoven. OUTLINE. History

gyan
Download Presentation

Principles of WHO Guidelines on nonclinical evaluation of vaccines.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Principles of WHO Guidelines on nonclinical evaluation of vaccines. Jan Willem van der Laan Pharmacological-Toxicological Assessment Section Centre for Biological Medicines and Medical Technology National Institute for Public Health and the Environment, Bilthoven

  2. OUTLINE • History • Regulatory documents • WHO Guideline on nonclinical evaluation of vaccines • Toxicity testing of GMOs

  3. History • Animal experiments as batch release testing • Potency testing • Abnormal Toxicity • Sensitizing potential • Immunogenicity • Adjuvants: No separate issue • Aluminium hydroxide, • Aluminium phosphate

  4. Regulational history • VACCINES under European legislation since 1993 • differentiation of pharmaceutical and non-clinical parts • overlap between potency testing and vaccine pharmacodynamics • direct pharmacological effects adrenergic receptors in autonomous nervous system, e.g. pertussis toxin, Heamophilus influenza, cholera toxin • overlap between batch release abnormal toxicity, non-clinical safety (in view of the developments in biotechnology) leading to • EU Guidance on Preclinical Pharmacological and Toxicological Testing of Vaccines CPMP/SWP/465/95

  5. Other Non-clinical Guidance Documents • Guideline on Adjuvants in Human Vaccines CHMP/VEG/17/03, draft released for consultation, March 2004final to be expected January 2005 • WHO Guidelines on Nonclinical evaluation of vaccines, released November 2004

  6. WHO Guidelines on Nonclinical Evaluation of vaccines • Nonclinical evaluation plays an essential part in the overall development of vaccine candidates • Product characterization • Proof of concept/immunogenicity • Safety testing in animals

  7. Aims of Non-clinical Testing of Vaccines • Identify possible risks to the vaccinees • Help to plan protocols

  8. Limitations of animal experiments • Pathogenesis and immune responses are frequently species-specific • Potential Safety concerns may not necessarily indicate a problem in humans

  9. SCOPE of the WHO Guidelines • Vaccines are a heterogenous class of immmunogenic substances inducing specific active protective host immunity against infectious disease.

  10. Vaccines • Inactivated Micro-organisms • Live Micro-organisms • Antigens extracted from micro-organisms • Chimeric micro-organisms • Antigens produced in vivo (DNA-vaccines)

  11. Characterization of candicate vaccines • Vaccine production • Potency • Stability

  12. Immunogenicity and other Pharmacodynamic studies • Proof of concept • Establish immunological characteristics • Help to select the doses and schedules Designed to assess relevant immune responses leading to protection

  13. Antigen Specific adjuvant skin Antigen presenting cell Immune response is triggered T-Cells B-Cells, antibodies

  14. Basic toxicity assessment • 4.1 General framework for designing pre-clinical toxicity of a vaccine (prior to initiation of clinical trials in humans) • 4.2 Additional considerations for specific toxicity assessments

  15. Study design • Relevant animal species/strain • Dosing schedule • Route of administration • Method of vaccine administration (specific device?) • Timing of evaluation of endpoints

  16. Animal species • Ideally, sensitive to the pathogenic organism • Develop an immune response to the vaccine antigen In general, one species is sufficient

  17. Dose, schedule and route of administration • Dose maximizing exposure and peak antibody response • Vaccine should be given as episodic doses based on the kinetics of the antibody response • Clinical route of administration is preferred

  18. Parameters monitored • In-life parameters • Daily observations • Weekly body weight and food consumption (1st week more frequent) • Interim analysis of heamatology and serum chemistry • Not only during treatment but also a few weeks after

  19. Parameters monitored (2) At study termination: • Parameters mentioned • Immune response • Gross necropsy, tissue collection and preservation

  20. Tissue list • Pivotal organs: brain, liver, kidney, reproductive organs, SoA. • Special attention to immune organs • Lymph nodes • Thymus • Spleen • Bone marrow • Peyer’s patches

  21. Additional toxicity assessments Specific Immunologic Investigations • Precipitation of immune complexes • Humoral or cell-mediated immune response against self (molec. mimicry) • Exacerbation of the disease

  22. Additional toxicity assessments (2) • Developmental toxicity studies • Usually not needed in case of paediatric vaccines • If WoCBP are included • Pre- and postnatal developmental study only

  23. Additional toxicity assessments (3) • Developmental toxicity study design • premating treatment is recommended to assure maximal exposure • Number of doses depends on the response • Booster immunization may be necessary to expose the embryo to vaccine components

  24. Safety pharmacology • If a vaccine (based on specific toxoids) is expected to affect physiological functions (CNS, respiratory, cardiovascular, renal) safety pharmacology studies should be performed

  25. Pharmacokinetic studies • Determining serum concentration is normally not needed • Local deposition studies at the site of injection and the draining lymph node • Distribution studies in case of new formulations, adjuvants or route of administration

  26. Special considerations • Adjuvants • Additives (excipients and preservatives) • Vaccine formation and delivery device

  27. What about plant vaccines? • Oral administration • Immunogenicity? • Immunobioavailability • What are the risks? • Immunotolerance • hypersensitivity

  28. What about plant vaccines? (2) • Plant constituents (alkaloids, proteins)? • Induces insertion pleiotrophic effects on plant toxoids?

  29. GMO Legislation • GM Crops – is there a safety issue? Novel gene Novel protein Novel food/food ingredient Gene transfer Toxicity (animal tests) Allergenicity Substantial equivalence Toxicity (animal tests) Unintended effects Kleter and Kuiper (2002)

  30. Safety assessment of GM foods • Molecular characterization • Changes in agronomical characteristics, morphology, and food composition • Toxicity of newly inserted proteins and of the whole food • Allergenicity • Gene transfer • Changed pattern in pesticide residues

  31. Safety assessment of GM foods • Principle of “Substantial Equivalence” • Assessment in a comparative way, i.e. new crop vs. conventionally bred crop

  32. Detection of unintended effects • Compared to convential crop based on phenotype based on: • Genomics - cDNA profile (microarray) • Proteomics – protein profile • Metabolomics – metabolite profile

  33. Toxicity studies for GM food proteins • Acute oral toxicity – one high dose • Subchronic oral toxicity (28-90 days)

  34. Allergenicity • Comparison by computer of structure with known allergens • Reactions of antisera of patients • Simulated digestion of novel proteins • Animal models, e.g. Brown-Norway rat (IgE-hyperresponsive)

  35. Thank you

More Related